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Clinical PerspectiveLabor and delivery guidance for COVID-19
Rupsa C. Boelig, MD, MS; Tracy Manuck, MD; Emily A. Oliver, MD; Daniele Di Mascio, MD; Gabriele Saccone, MD;
Federica Bellussi, MD; Vincenzo Berghella, MDoronavirus disease 2019 (COVID-This document addresses the current coronavirus disease 2019 (COVID-19) pandemic
for providers and patients in labor and delivery (L&D). The goals are to provide guidance
regarding methods to appropriately screen and test pregnant patients for COVID-19 prior
to, and at admission to L&D reduce risk of maternal and neonatal COVID-19 disease
through minimizing hospital contact and appropriate isolation; and provide specific
guidance for management of L&D of the COVID-19epositive woman, as well as the
critically ill COVID-19epositive woman.
The first 5 sections deal with L&D issues in general, for all women, during the COVID-19
pandemic. These include Section 1: Appropriate screening, testing, and preparation of
pregnant women for COVID-19 before visit and/or admission to L&D Section 2: Screening
of patients coming to L&D triage; Section 3: General changes to routine L&D work flow;
Section 4: Intrapartum care; Section 5: Postpartum care; Section 6 deals with special
care for the COVID-19epositive or suspected pregnant woman in L&D and Section 7
deals with the COVID-19epositive/suspected woman who is critically ill. These are
suggestions, which can be adapted to local needs and capabilities.
Key Words: coronavirus, COVID-19, obstetric protocol, pandemicC 19) is a global pandemic caused by
a novel coronavirus called severe acute
respiratory syndrome coronavirus 2.
Currently, more than 100 million
women are pregnant worldwide, and
virtually all of them are at a risk of con-
tracting COVID-19. Because pregnant
women have a suppressed immune sys-
tem, they may be at an increased risk of
developing severe or critical disease
associated with COVID-19, in particular
pneumonia and respiratory failure. Early
data from ameta-analysis of 41 pregnant
women with COVID-19 showed that
they may be at increased risk of miscar-
riage, preterm birth, preeclampsia, and
cesarean delivery (CD), particularly if
they are hospitalized with pneumonia.1
Their babies are at a higher risk of still-
birth (2.4%, 1/41), neonatal death (2.4%,
1/41), and admission to the intensive care
unit.1 Asymptomatic women and women
with mild disease have fewer complica-
tions. General guidance on the preven-
tion and management of COVID-19 in
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https://doi.org/10.1016/j.ajogmf.2020.100110addition, maternal-fetal medicine guid-
ance for COVID-19, with respect to
outpatient prenatal care, has been
recently published.6 It is currently esti-
mated that more than one-third and up
to two-thirds of the world population
may be infected with COVID-19
virus.7e9 Many of the 145 million
annual births worldwide are at risk,
including about 400,000 babies born
daily. This document addresses the cur-
rent COVID-19 pandemic for providers
and patients in labor and delivery (L&D).
The goals are as follows:
C To provide guidance regarding
methods to appropriately screen and
test pregnant patients for COVID-
19 before, and at admission to L&D
C To reduce the risk of maternal and
neonatal COVID-19 disease
through minimizing hospital con-
tact and appropriate isolation
C To provide specific guidance for
management of L&D of COVID-
19epositive and critically ill
COVID-19epositive women
The first 5 sections deal with L&D is-
sues in general, for all women, during theCOVID-19 pandemic and are as follows:
(1) appropriate screening, testing, and
preparation of pregnant women for
COVID-19 before visit and/or admission
to L&D; (2) screening of patients coming
to L&D triage; (3) general changes to
routine L&D work flow; (4) intrapartum
care; and (5) postpartum care. Section 6
deals with special care for COVID-19e
positive or suspected pregnant women in
L&D, and section 7 deals with COVID-
19epositive women and women sus-
pected of having COVID-19 who are
critically ill.
These are suggestions that can be
adapted to local needs and capabilities.
Guidance is changing rapidly; therefore,
one must continue to watch for
updates. A website that is constantly
being updated with COVID-19 preg-
nancy-specific guidance for both
providers and patients is www.
pregnancycovid19.com.
Section 1: Appropriate Screening,
Testing, and Preparation of Pregnant
Women for COVID-19 Before Visit
and/or Admission to L&D
Suggested outpatient management of
pregnant women with and withoutMAY 2020 AJOG MFM 1
FIGURE 1
Flowchart for triaging patients who call into labor and delivery. COVID-19, coronavirus disease 2019; PPE,
personal protective equipment
Boelig et al. Labor and delivery guidance for COVID-19. AJOG MFM 2020.
Clinical Perspectivesymptoms of COVID-19 has already
been described.6 Inpatient management
of pregnant women is similar to outpa-
tient recommendations with regard to
minimizing and eliminating all unnec-
essary contact of the patient with the
hospital or birth center to optimize so-
cial distancing. In most cases, necessary
patient-provider contacts should be
made through telehealth or remotely,
unless the patient describes an urgent
problem.6
Phone calls to L&D should be triaged
as shown in Figure 1. Patients calling with
symptoms of COVID-19 or influenza or
with direct contacts who have no urgent
obstetric issues should be referred for
testing outside of the hospital as per local
protocols, for example, through outside
drive-through testing centers. Women
without urgent obstetric issues awaiting
results should stay at home to self-isolate.
Those with urgent obstetric issues (eg,2 AJOG MFM MAY 2020labor, rupture of membranes, vaginal
bleeding), should be evaluated in an L&D
area dedicated to patients with COVID-
19. Providers should follow up on test
results and notify the team of any positive
test results.
Labor presents a unique scenario in
the COVID-19 pandemic, as all hospital
admissions are anticipated and the
timing of many admissions to the hos-
pital is planned. In anticipation of hos-
pital admission and to limit the risk of
exposure, women should be instructed
to discontinue work or begin working
from home a minimum of 2 weeks
before the anticipated date of delivery
and to practice strict social isolation
during this time. For most women, this
should be initiated at about 37 weeks.
In addition, L&D units should prepare
simulations of the COVID-19
pandemic, including for donning per-
sonal protective equipment (PPE) andso on. They should appropriate desig-
nated rooms and operating rooms
(ORs). For women with planned ad-
missions for induction of labor or ce-
sarean section, consider screening each
individual and her birthing partner by
a telephone call the day before
admission.
Section 2: Screening of Patients
Coming to L&D Triage
When women arrive at L&D, a desig-
nated staff member at the front of the
unit (eg, patient access coordinator, unit
coordinator) should verbally screen each
individual for upper respiratory tract
infection (URTI) symptoms. Any
woman reporting fever, cough, or res-
piratory symptoms should be given a
surgical mask and evaluated by a regis-
tered nurse or obstetric care provider.
The recommended flow is presented in
Figure 2. All birthing partners should be
FIGURE 2
Suggested flow for screening patients presenting to labor and delivery triage. COVID-19, coronavirus disease
2019; PPE, personal protective equipment
Boelig et al. Labor and delivery guidance for COVID-19. AJOG MFM 2020.
Clinical Perspectiveverbally screened; if they screen positive,
they should not be permitted to L&D
and should be directed to appropriate
testing or medical care as indicated.
Where testing capacity allows, universal
testing of all labor admissions should be
performed due to the likely high rate of
asymptomatic COVID-19epositive pa-
tients.10 If universal testing is not
possible, a screening algorithm as in
Figure 2 should be followed.
Important considerations in the care of
patients who screen positive
Appropriate isolation and sanitation.
 All healthcare providers should be
following the PPE recommendationsby the Centers for Disease Control
and Prevention (CDC) until COVID-
19 has been ruled out.
 Current CDC recommendations
include the use of a surgical mask,
protective eyewear, gown, and gloves.
An N-95 mask should be utilized, if
available, for any women with
confirmed or suspected COVID-19.11
 Aerosolization should in general be
avoided because it increases the
spread of the virus. If absolutely
necessary, N-95 masks should be
used in setting of aerosolization,
including if patient is on bilevel
positive airway pressure, has a tra-
cheostomy, requires high-flow nasal
cannula O2, or when administeringnebulized medications. Second
stage of labor is likely high risk for
aerosolization, and N-95 mask
should be used.12,13 The CDC has
indicated that N-95 masks are as
effective as powered air-purifying
respirators and should be used for
protection in the event of short-
term exposure.11
 Practice vigilant hand hygiene.
Management of patients who screen positive.
 Acute complaint requiring evalua-
tion (severe symptoms, labor
complaint, etc.):
o A special room should be reserved
as space allows for patients whoMAY 2020 AJOG MFM 3
Clinical Perspectivescreen positive (eg, URTI symp-
toms, fever), for both triage and
labor.
 Scheduled CD or induction of labor:
o Ideally, this should be determined
when screening the patient by
phone the day before admission to
avoid travel to the hospital (as
suggested above).
o Evaluation should be conducted to
determine if rescheduling in 2e3
days is feasible to allow for results
of COVID-19 testing if necessary.
o For COVID-19epositive patients
with mild or moderate symptoms
not requiring immediate care, it is
important to recognize that the
severity of disease peaks often in
the second week; therefore, plan-
ning delivery before that time is
optimal.
Section 3. General Changes to
Routine L&D Work Flow
Respiratory precautions and PPE
Given the risk of asymptomatic carriers
and transmission,10 it should be the goal
of every unit that every patient wear a
surgical mask and that every provider
should have a surgical mask for each pa-
tient encounter.14,15 However, the ability
to execute this recommendation is obvi-
ously limited by supply. For any patients
with respiratory symptoms, full droplet
precautions should be utilized, including
the use of gloves, gown, and surgicalmask
with a face shield. N95 mask should be
worn in addition to droplet precaution
PPE for any patients with suspected or
confirmed COVID, and for any patient,
regardless of respiratory symptoms, during
indispensable aerosol-generating pro-
cedures, including the second stage of
labor.11,16 As much as possible, oxygen
should not be given aerosolized. In
addition, hand hygiene with alcohol-
based handrub after every patient con-
tact and appropriate donning and doffing
of PPE are critical.11e17 Finally, rooms
that are exposed need to be wiped down
as respiratory viruses may spread from
surface contact.18 These aggressive mea-
sures can help limit transmission in pro-
viders in a healthcare setting. Table 1
summarizes our recommendations.4 AJOG MFM MAY 2020Visitor policy
Given the significant risk of COVID-
19 transmission between patients,
families, and healthcare providers,
there should be strict restrictions on
visitor policy.
 L&D
o Visitation should be limited to 1
support person, in-person. Pref-
erence is for support through
video, if patient agrees. All in-
person support people should be
screened as per Section 2. The
support person should be easily
identifiable by L&D staff; one
suggestion would be to provide
them with a special colored wrist
band that must be worn at all
times. Switching of visitors will
not be permitted. Given the
public health emergency, no
additional in-person support
people should be allowed,
including doulas.
 Antepartum and postpartum
o There should be a designated sup-
port person for the entire admis-
sion. This should be the same
designated person as for delivery.
 Neonatal intensive care unit
o Parents may visit in the neonatal
ICU one at a time.
 No children younger than 16e18
years will be permitted at any time.
 Additional visitors for end-of-life
situations may be considered and
evaluated on a case-by-case basis.
Visitation may be further restricted at
the discretion of unit leadership and as
the outbreak evolves.
Patient admissions and location
In general, all efforts should be made to
limit the movement of women from one
care area to another (eg, triage room to
antepartum room to L&D room). Ad-
missions for delivery should remain on
L&D; consider admitting stable admis-
sions for antepartum monitoring
directly to the antepartum unit. For
example, consider holding a woman
with preterm prelabor rupture of
membranes in triage for continuousmonitoring and observation for a
longer period than what might typi-
cally occur, and then transferring her
directly to the antepartum unit rather
than moving her to an L&D room as an
intermediary stop.
Pre-CD laboratory tests
To limit multiple visits to a healthcare
setting, women should undergo routine
preoperative laboratory tests (eg, com-
plete blood cell count, type and screen)
on the day of their CD.
Section 4: Intrapartum Care
Inductions of labor
Inductions of labor with medical in-
dications in asymptomatic women
should not be postponed or rescheduled.
This includes inductions at 39 week of
pregnancy, after patient counseling.19
However, in cases of extreme healthcare
system burden (see Section 2), it may be
appropriate to consider postponing or
rescheduling the induction. This
recommendation will vary depending on
the current state of the COVID-19
pandemic. For example, in a region
with early COVID-19 emergence, it may
be prudent to proceed with delivery
before high COVID-19 burden in the
hospital. For sites with an existing high
COVID-19 burden, an additional stay of
1e2 days in the hospital, occupying a
hospital bed, for an induction of labor
may not be possible. Other site-specific
and COVID-19especific considerations
may include options such as beginning
the induction process at home to limit
in-hospital time (eg, outpatient Foley
bulb cervical ripening). Induction can
still be conducted as usual, with a com-
bination of 60- to 80-mL single-balloon
Foley for 12 hours and either oral 25-
mcg misoprostol initially, followed by
25mcg every 2e4 hours, or 50mcg every
4e6 hours (if no more than 3 contrac-
tions per 10 minutes or previous uterine
surgery), or oxytocin infusion.20
Outpatient Foley cervical ripening can
be considered for low-risk women, to
minimize contacts. CD should not be
performed before 15 hours of oxytocin
and amniotomy if feasible, and ideally
after 18e24 hours of oxytocin.20
TABLE 1
Suggested PPE based on clinical situation
Individual and clinical situation Surgical mask
Droplet PPE (gown,
gloves, surgical
mask/face shield) N-95 mask
Patient (with or without respiratory symptoms) X
Provider during routine patient encounter X
Provider during contact with patient with suspected or
confirmed COVID-19
X X
Provider caring for patient during aerosol-generating
procedure including second stage of labor
X X
COVID, coronavirus disease 2019; PPE, personal protective equipment; URTI, upper respiratory tract infection.
Boelig et al. Labor and delivery guidance for COVID-19. AJOG MFM 2020.
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General guidance.Management of the
first stage should not be altered, unless
specified below. Intrapartum antibiotic
prophylaxis is recommended for group
B Streptococcusepositive patients, im-
mersion in water in the first stage of
labor can be considered, oral restriction
of fluid or solid food in the first stage of
labor is not recommended, and oral
administration of water and clear fluids
can be encouraged as tolerated in labor.
In case of oral restriction, intravenous
fluid containing dextrose at a rate of 125
mL/h; given the significant risk of
asymptomatic carriers especially in the
absence of universal testing, there
should be conscious use of fluids. Up-
right positions in the first stage of labor
are recommended in women without
regional anesthesia, women with
regional anesthesia in the first stage can
take whatever position they find most
comfortable, and walking should be
recommended in the first stage of labor
in women without regional anesthesia,
but in the delivery room. Women with
regional anesthesia can walk or not walk
in the first stage of labor; continuous
bladder catheterization cannot be rec-
ommended in labor, and routine use of
peanut ball cannot be recommended in
labor because it has not been shown to
be beneficial and may be a way to
transmit infection. Oxytocin augmen-
tation is recommended to shorten the
time to delivery for women making slow
progress in the first stage of spontaneouslabor; higher doses of oxytocin can be
considered; early intervention with
oxytocin and amniotomy for the pre-
vention and treatment of dysfunctional
or slow labor is recommended; CD for
arrest in the first stage of labor should
not be performed unless labor has
arrested for a minimum of 4 hours with
adequate uterine activity, or 6 hours
with inadequate uterine activity in a
woman with rupture of membranes,
adequate oxytocin, and 6-cm dilated
cervix.20
Oxygen therapy. Although oxygen via
nasal cannula is not considered an
aerosol-generating procedure, the fact
that nasal cannula or face mask are in
contact with maternal respiratory tract
and secretions makes handling of such
equipment (taking on, taking off, or
adjusting) can lead to a greater possi-
bility of contamination or exposure be-
tween patient and provider. A recent
meta-analysis has demonstrated that
intrapartum oxygen has no fetal benefit
and may cause harm.21,22 In the current
scenario wherein reducing the risk of
COVID-19 spread among healthcare
providers and patient is paramount,
there is even more reason to not utilize
oxygen therapy for fetal resuscitation.
Given the likely high rate of asymp-
tomatic carriers,23 this principle applies
regardless of patient’s COVID-19 status.
Nitrous oxide. The use of nitrous oxide
involves risk of aerosolization andinvolves respiratory contamination.
Eliminating nitrous oxide use
during COVID-19 pandemic is
recommended.24
Second stage
Management during the second stage of
labor should not be altered, unless
specified as in Section 6. See general and
specific guidance for first stage, much of
which applies to the second stage as well.
Pushing should not be delayed because it
prolongs time to delivery and increases
chorioamnionitis and postpartum
hemorrhage.25,26 Perineal massage27 and
warm packs28 are each associated with
decrease in third and fourth degree
lacerations.
Third stage
There are concerns regarding limited
resources for blood transfusion because
of inability to run blood drives. Given
this situation, all care should be taken to
reduce the need for blood transfusion,
including optimizing antenatal hemo-
globin before delivery. In addition to
standard oxytocin, consideration should
be made for prophylactic tranexamic
acid and misoprostol (400 mcg
buccally).29 The use of cell-salvage dur-
ing CD should be considered after
stratification of risk for postpartum
hemorrhage and institutional capabil-
ities. If blood transfusion is indicated
and hemorrhage is not ongoing, begin
with transfusion of 1 unit rather than the
typical 2 units of packed red blood cells,MAY 2020 AJOG MFM 5
Clinical Perspectivethen reassess the clinical need for the
second unit.
Some have advocated for avoiding
delayed cord clamping, even if vertical
transmission has not been confirmed at
the time of the submission of this
manuscript.
Anesthesia considerations
The Society for Obstetric Anesthesia and
Perinatology has published interim
guidelines based on expert opinion. As
with other COVID-19 guidelines, these
are rapidly evolving.24
 Early epidural should be used to
minimize need for general anesthesia in
the event of emergent cesarean section.
 COVID-19 is not a contraindication
to neuraxial anesthesia.
 Consider stopping nitrous oxide use
due to potential risk of aerosolization.
Section 5: Postpartum Care
Women should be notified that they will
be discharged in an expedited and safe
fashion to limit the risk of infection to
themselves, staff, and other patients.
Expedited discharge planning
 All vaginal deliveries should have a
goal of discharge on postpartum day
1, or even the same day if possible for
selected women.
 All CDs should have a goal of
discharge on postoperative day 2, with
consideration of postpartum day 1
discharge if meeting milestones.
 Anticipated maternal discharge
should be discussed with pediatrics/
neonatology to determine timing of
infant discharge.
 Home care with supplies for blood
pressure follow-up will be critical to
expediting discharge of patients with
a hypertensive disorder.
Postpartum visit
 All postpartum visits, including
wound checks, should be arranged for
telehealth. Postpartum evaluation of
cesarean wound healing or mastitis
concerns may be optimized through
the use of photo upload options
available in many electronic medical
record patient portal programs.6 AJOG MFM MAY 2020Encourage either long-acting revers-
ible contraceptive placement or
Depo-Provera injection before
discharge for patients planning to use
these to eliminate need for additional
in-person postpartum visits.
Section 6: Care for the Suspected or
Confirmed COVID-19ePositive
Pregnant Patient in L&D
Obstetric medications
Two commonly used medications in
obstetrics have been the source of study
and controversy in the setting of
COVID-19 pandemic; nonsteroidal
anti-inflammatory drugs (NSAIDs), in
particular indomethacin, are commonly
used for tocolysis, and steroids, specif-
ically betamethasone or dexamethasone,
are used for fetal lung maturity. In
addition, we will also address the use
of magnesium, given the respiratory
morbidity of COVID-19 (Table 2).
Indomethacin. There were early reports
postulating that NSAIDsmay worsen the
course of COVID-19. The virus binds to
cells through the angiotensin-converting
enzyme-2 (ACE-2) receptor; thus, it was
postulated that NSAIDs, which increase
ACE-2 expression, may result in wors-
ening of the disease.30 However, this has
not been substantiated, and multiple
organizations, including the World
Health Organization (WHO) and the
Food and Drug Administration (FDA)
have advocated there should not be a
restriction on NSAID use.31 In the
setting of tocolysis, nifedipine may be
considered as an alternative given the
uncertainty regarding the impact of
NSAIDs on COVID-19. These recom-
mendations may change as additional
data emerge.
Betamethasone/dexamethasone. The
routine use of systemic corticosteroids
in case of a viral pneumonia has been
associated with increasedmorbidity.32,33
One study showed delayed viral clear-
ance with the use of corticosteroids in
those with Middle East respiratory syn-
drome.34 Specifically with COVID-19,
there is an association between steroid
use and mortality, although these
studies do not control for baselinemorbidity.35,36 Generally, steroid use
evaluated in these studies is higher than
a 2-day course of steroids; however,
given the association between steroids
and worsening morbidity of viral
pneumonia and specifically COVID-19,
judicial use of steroids for fetal lung
maturity is recommended. It should be
noted that the dose of steroids used for
fetal lung maturity are lower than the
systemic doses that have been used and
studied in the setting of COVID-19 and
other respiratory conditions. Consider
Table 2 for steroid use for fetal lung
maturity balancing benefit by risk of
delivery within the next 7 days, gesta-
tional age, and potential risk based on
maternal presentation. These recom-
mendations are supported by the
WHO.5
Magnesium sulfate.Magnesium sulfate is
indicated for neuroprotection when de-
livery is anticipated <32 weeks or for
eclampsia prophylaxis.37,38 There are no
reported data regarding the impact of
magnesium sulfate on COVID-19.
However, given the potential respira-
tory complications with the use of
magnesium sulfate, it should be used
judiciously in case of severe respiratory
symptoms with careful consideration of
both total fluids administered and kid-
ney function. Magnesium sulfate may be
used as indicated in patients withmild or
moderate symptoms.
Laboratory value changes
There are some changes noted with
COVID-19 that have important impli-
cations in care for the pregnant patients.
Specifically, COVID-19 may be associ-
ated with transaminitis, elevated creati-
nine, and thrombocytopenia.35 This is
an important consideration in a patient
presenting with a hypertensive disorder
in assessing whether she has severe fea-
tures of preeclampsia, hemolysis,
elevated liver enzyme levels, and low
platelet count syndrome, versus mani-
festation of COVID-19.
Intrapartum care
C Delivery timingo COVID-19 severity peaks in the
second week; thus, it may be
TABLE 2
Use of common medications in preterm labor management for pregnant patients with COVID-19














Indomethacin May consider if nifedipine
not an option











Severe signs or symptoms include need for respiratory support, hypoxia, etc.
COVID, coronavirus disease 2019; ID, Infectious Disease.
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Clinical Perspectiveprudent to expedite delivery of
term COVID-19epositive pa-
tients with only mild symptoms.C Mode of delivery
o COVID-19 alone is not an indi-
cation for a CD.
o Delivery mode should be dictated
by obstetric indications.
C Risk of vertical transmissiono There has been no documented
vertical transmission as of the
date of our submission based on
limited case series39,40 of which
89% had cesarean sections.C Precautions for transmission
prevention
o Designate nearby rooms, or a




- Room type: negative pressure
room is not required.
- If a patient has known
COVID-19 or high suspicion
for it, PPE should be used per
hospital-specific guidelines.
At a minimum, an N95 mask
and full droplet precaution
should be used by the pro-
viders in the room during the
second stage of labor.
- Minimize change in providers.
Depending on the volume of
COVID-19epositive patients,consider having a team desig-
nated for confirmed or sus-
pected cases of COVID-19.C Medical care




ric anesthesia, and Neonatology
o Consult Maternal Fetal Medicine
regarding the use of steroids for
fetal maturity, indomethacin, and
magnesium sulfate (Table 2).
o Refer to intrapartum oxygen use
guideline. Given the lack of fetal
benefit, and risk of contamina-
tion or transmission with the use
of an intranasal device, we do not
recommend the use of oxygen for
fetal resuscitation in any patient,
suspected case of COVID-19 or
otherwise
o Fluid restriction (total fluids<75
cc/h) unless there is concern for
sepsis or hemodynamic
instabilityC CD
o Designate, when possible, 1 OR
for use for the suspected or
confirmed COVID-19 patient
and have appropriate PPE
outside the OR door.
o A designated PPEmonitor should
be assigned to ensure proper
donning and doffing of PPE.o Appropriate planning, including
simulation training, should be
done regarding planned, urgent,
and emergent CD. Figure 3 pre-
sents a suggested flow to consider.
Aspects to take into consideration
include PPE placement in or near
the OR to minimize time required
for donning PPE in case of emer-
gent CS,which providers will need
additional PPE for direct patient
contact, minimizing the number
of providers involved in direct
patient contact, etc.Postpartum care
C Although breastfeeding is still
encouraged (no evidence of
COVID-19 transmission through
breastmilk), given the riskof neonatal
morbidity from transmission
throughmaternal exposure, the CDC
does recommend the separation of
mother and neonate.
C Breastfeeding considerations
o Breast milk provision (by
pumping) is encouraged and is a
potentially important source of
antibodies for the infant. The
CDC recommends that during
temporary separation, women
who intend to breastfeed should
be encouraged to express their
breast milk to establish and
maintain milk supply.MAY 2020 AJOG MFM 7
FIGURE 3
Flow chart for roles, equipment, and PPE in preparation for a cesarean delivery of COVID-positive patient
COVID, coronavirus disease; OB, obstetrician; OR, operating room; PPE, personal protective equipment; RN, registered nurse.
Boelig et al. Labor and delivery guidance for COVID-19. AJOG MFM 2020.
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8 Ao Before expressing breast milk,
women should practice appro-
priate hygiene not just for hands
but also for breasts before
pumping.
o After pumping, all parts of the
pump that come in contact with
breast milk should be thoroughly
washed, and the entire pump
should be appropriately dis-
infected per the manufacturer’s
instructions.
o Expressed breast milk should be
fed to the newborn by a healthy
caregiver.
o For women and infants who are
not separated, the CDCJOG MFM MAY 2020recommends that if a woman and
newborn do room-in and the
woman wishes to feed at the
breast, she should put on a mask
and practice hand hygiene before
each feeding.41C Pain control
o The current FDA and WHO
guidelines are not to restrict
NSAID use. We support
continued use of acetaminophen
and ibuprofen for pain control
and do not suggest increased
narcotic use to replace ibuprofen
or NSAIDs. These general rec-
ommendations may be modified
depending on patient-specificmorbidity and as we have more
information regarding the asso-
ciation between NSAIDs and
COVID-19 severity.31Section 7: Care of the Critically Ill
COVID-19 Pregnant Patient
All critically ill COVID-19 patients
should be in isolation as per hospital
protocol. PPE equipment should be
outside the patient’s room or unit if
it is a dedicated COVID-19 unit.
Fetal well-being
C Corticosteroids: Given the poten-
tial risks of systemic steroids in
COVID-19, steroids for fetal
Clinical Perspectivematurity should be used judi-
ciously, balancing the benefit by
gestational age with potential risks
of worsening maternal morbidity.
Decisions regarding the use of
corticosteroids for fetal lung
maturity should be made in con-
cert with critical care team and
neonatology.
C For patients >24 weeks of preg-
nancy, electronic fetal monitoring
for antenatal surveillance should be
performed at least daily and with
any change inmaternal status if a CD
at bedside is feasible. The fetus can
be a “sixth” vital sign reflecting early
deterioration in maternal status.
C As per usual obstetric care, goal for
saturations should be maintained
>95%.
Maternal medical care
Special consideration should be given to
normal maternal respiratory physiology
and how this affects management of the
acute respiratory distress syndrome
(ARDS):
Pregnancy involves a natural respira-
tory alkalosis with a normal PCO2 of 28
to 32 mm Hg.42
Therapy for ARDS involves low tidal
volumes and permissive hypercapnia
(PCO2<60 mm Hg).
43 Data on permis-
sive hypercapnia in pregnancy are
limited, but there do not appear to be
adverse fetal affects.44
C In the third trimester, increased
positive end-expiratory pressures
may be required.
C Goal for blood pressure should be
<160/110 mm Hg.
C Patient should be positioned with left
lateral tilt (if no other position is
mandated for their treatment, eg,
prone position) to relieve pressure
from gravid uterus on venous return.
C Prone positioning may be used as
necessary with appropriate support
of gravid abdomen.
Delivery planning
C Preparationo Equipment for an emergent CD
should be available at the bedside,
including neonatal equipment.o A hemorrhage kit, which in-
cludes Methergine, Hemabate,
and misoprostol, should be at
the bedside. Tranexamic acid
needs to be refrigerated but
should be requested for all de-
liveries and readily available in
the ICU.
o The use of terbutaline should be
reviewed with the critical care
team, depending on the patient’s
clinical status owing to risk of
tachycardia
o An effective method of commu-
nication for the anesthesia team,
neonatology team and obstetric
team should be implemented.
o If an emergent delivery is plan-
ned, this should be performed at
the bedside in the ICU to avoid
transferring the patient.C Timing
o Consideration should be given to
delivery >34 weeks for the criti-
cally ill pregnant patient. Delivery
can help optimize maternal res-
piratory status. This should be
balanced with the potential risk
of catecholamine surge, auto-
transfusion, and fluid shifts that
could potentially exacerbate
maternal condition.C Intrapartum care
o If a critically ill pregnant patient
at term goes into labor, the
aforementioned precautions
should be initiated.
o An assisted second stage of labor
is likely to be necessary.
o A dedicated obstetrician should
be assigned to the patient with
minimal change in providers, as
the situation allows.
o The neonatology team should be
present at the time of delivery,
and the infant should be placed in
isolation after delivery, given the
unknown risks of transmission.
o Prevention of postpartum hem-
orrhage should occur as detailed
above.Postpartum care
C The infant should be separated as
soon as possible and transferred to
an isolation room appropriately.C The use of a breast pump is
encouraged, after review ofmaternal
medications (see Section 6). -
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